Departmental Bulletin Paper Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine cervical cancer

Miyauchi, Risei  ,  Itoh, Yoshiyuki  ,  Kawamura, Mariko  ,  Hirakawa, Akihiro  ,  Shibata, Kiyosumi  ,  Kajiyama, Hiroaki  ,  Nakahara, Rie  ,  Kubota, Seiji  ,  Ito, Junji  ,  Okada, Tohru  ,  Kikkawa, Fumitaka  ,  Naganawa, Shinji  ,  Miyauchi, Risei

79 ( 2 )  , pp.211 - 220 , 2017-05 , Nagoya University Graduate School of Medicine, School of Medicine
The purpose of this retrospective study was to analyze data in patients with stage IB–IIB uterine cervical cancer who were treated with concurrent chemoradiotherapy (CCRT) with high dose cisplatin and fluorouracil as postoperative adjuvant therapy. Between February 2003 and November 2011, 76 patients with FIGO stage IB–IIB cervical cancer were analyzed. Seventy patients were treated with postoperative CCRT and 6 patients were treated with radiation therapy alone. Data related to overall survival (OS), disease-free survival (DFS), toxicity, and failure pattern were analyzed. The median patient age was 45 years (range, 20–80 years). The median follow-up duration was 63 months (range, 10–125 months). Fifty-eight patients (76.3%) had a squamous cell histologic type, 55 patients (72.4%) had lymphovascular invasion, 31 patients (40.8%) had parametrial invasion, and 28 patients (36.8%) had lymph node metastases. Five-year OS and DFS were 96% and 92%, respectively. Five-year DFS in stage IB1 patients was significantly higher than in stage IB2–IIB patients (p = 0.022). Nineteen patients (25%) had grade 3 or 4 neutropenia, 13 patients (17.1%) had grade 3 anemia, and 2 patients (2.6%) had grade 3 thrombocytopenia, but none of these patients died from the disease. Three patients experienced chronic toxicity: one had bladder perforation, one had hydronephrosis, and one experienced ileus. CCRT as postoperative adjuvant therapy resulted in good survival and outcome without severe toxicity.

Number of accesses :  

Other information